Nanotechnology in pulmonary medicine
10.1016/j.coph.2020.11.002 · doi-reference
Inhaled nanoparticles–An updated review
10.1016/j.ijpharm.2020.119671 · doi-reference
Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices
10.1080/10717544.2021.1981492 · doi-reference
Multifunctional nanocarriers for lung drug delivery
10.3390/nano10020183 · doi-reference
Rational development of a carrier-free dry powder inhalation formulation for respiratory viral infections via quality by design: a drug-drug cocrystal of favipiravir and theophylline
10.3390/pharmaceutics14020300 · doi-reference
Nebulised isotonic hydroxychloroquine aerosols for potential treatment of COVID-19
10.3390/pharmaceutics13081260 · doi-reference
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19, Med
10.1016/j.mehy.2020.110110 · doi-reference
Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: a patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion
10.1016/j.ijpharm.2021.121133 · doi-reference
Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients
10.7150/thno.46691 · doi-reference
Binding of chloroquine–conjugated gold nanoparticles with bovine serum albumin
10.1016/j.jcis.2010.12.032 · doi-reference
Development and in vitro evaluation of linear PEI-shelled heparin/berberine nanoparticles in human osteosarcoma U-2 OS cells
10.3390/molecules23123121 · doi-reference
Nanomedicine as a future therapeutic approach for Hepatitis C virus
10.2217/nnm-2018-0348 · doi-reference
Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19
10.2217/nnm-2020-0247 · doi-reference
Investigation of a pMDI system containing chitosan microspheres and P134a
10.1016/s0378-5173(98)00266-x · doi-reference
Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases
10.1016/s0009-2509(03)00234-3 · doi-reference
Lung lymphatic anatomy and correlates
10.1016/j.pathophys.2009.10.008 · doi-reference
Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD
10.1183/16000617.0112-2021 · doi-reference
Abundance of non-polarized lung macrophages with poor phagocytic function in chronic obstructive pulmonary disease (COPD)
10.3390/biomedicines8100398 · doi-reference
CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways
10.1183/16000617.0068-2019 · doi-reference
Nanocarriers for anticancer drugs: challenges and perspectives
10.1016/j.sjbs.2022.103298 · doi-reference
Giant frictional dissipation peaks and charge-density-wave slips at the NbSe2 surface
10.1038/nmat3836 · doi-reference
Factoring-in agglomeration of carbon nanotubes and nanofibers for better prediction of their toxicity versus asbestos, Part
10.1186/1743-8977-9-10 · doi-reference
Nanomaterial-based delivery of vaccine through nasal route: opportunities, challenges, advantages, and limitations
10.1016/j.jddst.2022.103533 · doi-reference
10.1021/ac061748o
10.1021/ac061748o · doi-reference
Nanotechnology: scientific challenges and societal benefits and risks
10.1007/s11661-004-0270-x · doi-reference
Nanorobotics control design: a collective behavior approach for medicine
10.1109/tnb.2005.850469 · doi-reference
Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment
10.1038/mt.2009.208 · doi-reference
Structural stability and optical properties of nanomaterials with reconstructed surfaces
10.1103/physrevlett.91.157405 · doi-reference
Effect of the size and surface charge of silica nanoparticles on cutaneous toxicity
10.1007/s13273-013-0010-7 · doi-reference
Nanotechnology risk perceptions and communication: emerging technologies, emerging challenges
10.1111/j.1539-6924.2011.01738.x · doi-reference
Deagglomeration of dry powder pharmaceutical aerosols
10.1016/s0378-5173(02)00319-8 · doi-reference
Inhalation drug delivery devices and emerging technologies
10.1517/13543776.13.9.1333 · doi-reference
Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes
10.1080/10611860600834375 · doi-reference
Nanoantioxidants: recent trends in antioxidant delivery applications
10.3390/antiox9010024 · doi-reference
Nanoparticle-mediated pulmonary drug delivery: a review
10.3390/ijms15045852 · doi-reference
Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method
10.3390/molecules25204781 · doi-reference
Pulmonary drug delivery Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications
10.1046/j.1365-2125.2003.01893.x · doi-reference
Polymeric nanoparticles in development for treatment of pulmonary infectious diseases
10.1002/wnan.1401 · doi-reference
Aerosol inhalation delivery of triazavirin in mice: outlooks for advanced therapy against novel viral infections
10.1016/j.xphs.2020.11.016 · doi-reference
Pulmonary delivery of hydroxychloroquine nanostructured lipid carrier as a potential treatment of COVID-19
10.3390/polym14132616 · doi-reference
